<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">AJAC</journal-id><journal-title-group><journal-title>American Journal of Analytical Chemistry</journal-title></journal-title-group><issn pub-type="epub">2156-8251</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ajac.2022.1312033</article-id><article-id pub-id-type="publisher-id">AJAC-121825</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Chemistry&amp;Materials Science</subject></subj-group></article-categories><title-group><article-title>
 
 
  Influence of Some Physico-Chemical Exposure Factors on the Carbocysteine Content of an Opened Pharmaceutical Product
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Jean-Kisito</surname><given-names>Kouame</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Mariette</surname><given-names>Desiree Yehe</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Carine</surname><given-names>Nina Able</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Vincent</surname><given-names>De Paul Ovi</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Hervé</surname><given-names>Tazoh Broh</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Claude</surname><given-names>Bérenger Ngalemo Ngantchouko</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Gildas</surname><given-names>Komenan Gbassi</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>National Public Health Laboratory (NPHL), Food Control Service, Abidjan, Ivory Coast</addr-line></aff><aff id="aff2"><addr-line>Department of Analytical Sciences and Public Health, UFR Pharmaceutical and Biological Sciences, Félix Houphou&amp;amp;euml;t Boigny University, Abidjan, Ivory Coast</addr-line></aff><pub-date pub-type="epub"><day>15</day><month>12</month><year>2022</year></pub-date><volume>13</volume><issue>12</issue><fpage>495</fpage><lpage>505</lpage><history><date date-type="received"><day>10,</day>	<month>November</month>	<year>2022</year></date><date date-type="rev-recd"><day>13,</day>	<month>December</month>	<year>2022</year>	</date><date date-type="accepted"><day>16,</day>	<month>December</month>	<year>2022</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  The aim of this study was to investigate the stability of Carbocysteine (CBC) contained in a reference substance (RS) and in a sample of opened RHINATHIOL
  <sup>&#174;</sup> 5% syrup (RNTL 5%) under the effect of some physicochemical parameters (temperature, light, time, pH, bile salts). The developed method was linear, precise and accurate according to USP 38. The co-efficient of determination R
  <sup>2</sup> for linearity was 0.9993. The respective RSD of intra-day and inter-day between days (1st, 2nd and 3rd day) were respectively 0.338% and the interval from 0.05% to 0.387%. The average recovery rate ranged from 98.490% to 100.450%. The detection and quantification limits were 0.0001 mg/mL and 0.001 mg/mL respectively. The method was applied to four samples of opened syrup containing CBC and the CBC content in these samples was found to be in accordance with USP 38. The CBC content in the opened sample of RNTL 5% was obtained by UV-visible spectrophotometry at 217 nm and was 4.887 g/100mL. The study of the influence of physico-chemical factors on the content of CBC in RS and RNTL 5% showed that the evolution of CBC contents in each drug matrix remained dependent on pH and temperature. However, these levels remained stable in the presence of light.
 
</p></abstract><kwd-group><kwd>Influence</kwd><kwd> Physico-Chemistry</kwd><kwd> Content</kwd><kwd> Carbocysteine</kwd><kwd> Stability</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>In developing countries, the problem of the stability of pharmaceutical products can have serious consequences on the health of the population such as the development of resistance to the usual treatment, and the deterioration of the state of health of the patient which can lead to death and the risk of fatal poisoning [<xref ref-type="bibr" rid="scirp.121825-ref1">1</xref>]. These consequences are caused by a decrease in the content of the active ingredient (API) contained in the drug, and the formation of numerous degradation products of preservatives and excipients [<xref ref-type="bibr" rid="scirp.121825-ref2">2</xref>].</p><p>In order to prevent these long-term problems, manufacturers have set up stability tests to determine the behaviour of the AP in the drug under different storage conditions in order to improve its stability [<xref ref-type="bibr" rid="scirp.121825-ref3">3</xref>]. These tests are recommended by the Q1A-Q1F standards established by the International Council for Harmonisation (ICH) of Technical Requirements for the Registration of Medicinal Products for Human Use [<xref ref-type="bibr" rid="scirp.121825-ref4">4</xref>]. However, the duration of validity of medicinal products attributed following these stability studies is not an infallible guarantee and remains dependent on the conditions of storage, transport, reconstitution or use [<xref ref-type="bibr" rid="scirp.121825-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.121825-ref6">6</xref>] [<xref ref-type="bibr" rid="scirp.121825-ref7">7</xref>]. Jassim A-M [<xref ref-type="bibr" rid="scirp.121825-ref8">8</xref>] and Shankar P. et al. [<xref ref-type="bibr" rid="scirp.121825-ref9">9</xref>] have illustrated in their various studies that medicines are stored inappropriately in households. This is the case in C&#244;te d’Ivoire where some patients keep their opened medicines in different storage conditions beyond the validity of the treatment [<xref ref-type="bibr" rid="scirp.121825-ref10">10</xref>].</p><p>In order to address the different conditions that can impact the stability of the active ingredient contained in a drug, the choice of CBC chemically called (2R)-2-amino-3-[(carboxy-methyl) sulphanyl] propanoic acid [<xref ref-type="bibr" rid="scirp.121825-ref11">11</xref>] was made for the realization of this study because it is very solicited in C&#244;te d’Ivoire in the treatment of recent respiratory affections with difficulty in spitting (difficulty in rejecting bronchial secretions by spitting) [<xref ref-type="bibr" rid="scirp.121825-ref12">12</xref>]. It is a molecule that appears as a white, crystalline powder, insoluble in water and alcohol. It dissolves in dilute solutions of mineral acids and alkali hydroxides [<xref ref-type="bibr" rid="scirp.121825-ref11">11</xref>]. It is derived from a thiolated amino acid (<xref ref-type="fig" rid="fig1">Figure 1</xref>) and its toxicity has only been evaluated in animals [<xref ref-type="bibr" rid="scirp.121825-ref13">13</xref>].</p><p>Several analytical techniques can be used to perform this study. These include High-Performance Liquid Chromatography (HPLC), Capillary Electrophoresis (CE), UV-visible Spectrophotometry [<xref ref-type="bibr" rid="scirp.121825-ref14">14</xref>], Fluorimetry [<xref ref-type="bibr" rid="scirp.121825-ref15">15</xref>] and Titrimetry [<xref ref-type="bibr" rid="scirp.121825-ref16">16</xref>] [<xref ref-type="bibr" rid="scirp.121825-ref17">17</xref>] [<xref ref-type="bibr" rid="scirp.121825-ref18">18</xref>]. UV-visible spectrophotometry was chosen for the implementation of this study because it is a popular analytical technique that allows the quality of a sample to be checked quickly and reliably [<xref ref-type="bibr" rid="scirp.121825-ref19">19</xref>].</p><p>The objective of this study was firstly to set up an assay method to quantify CBC in tapped samples and secondly to study the impact of some physico-chemical exposure factors on the CBC content of one of the tapped samples (the RNTL 5%).</p></sec><sec id="s2"><title>2. Materials and Method</title><sec id="s2_1"><title>2.1. Sampling</title><p>Four opened syrups containing CBC 5% with a shelf life of one year after use were used for this study (<xref ref-type="table" rid="table1">Table 1</xref>). RNTL 5% was used in the following for the study of influencing factors.</p></sec><sec id="s2_2"><title>2.2. Reference Substance and Chemicals</title><p>Carbocysteine (CBC) of 99% purity and batch number 5MJ175 supplied by the manufacturer GPHF (Global Pharma Heath Fund) was used as the reference substance (RS). Purified water and 0.1N NaOH (dilution solution) were respectively used throughout the study to prepare the different solutions. Solutions such as: 0.1N NaOH, 0.1N HCl and 0.54 mg/mL bile salt solution were used to carry out the study. These different solutions were obtained from reagents such as NaOH of 97% purity, HCl of 37% purity and bile salts of 100% purity. They were supplied by the manufacturers CARLO ERBA and FLUCA analytical.</p></sec><sec id="s2_3"><title>2.3. Apparatus</title><p>A double-beam UV-visible spectrophotometer SPECOR 210 PLUS from the manufacturer ANALYTIK JENA and a pH meter from HACH were used to measure the absorbance of the solutions obtained and to measure the pH of the different solutions, respectively.</p></sec><sec id="s2_4"><title>2.4. Method</title><sec id="s2_4_1"><title>2.4.1. Preparation of the Stock Solution of CBC Reference Substance (RS)</title><p>The stock solution of CBC RS was prepared by dissolving 10 mg of CBC in 10 mL of 0.1 N NaOH to obtain a solution of concentration 1 mg/mL.</p></sec><sec id="s2_4_2"><title>2.4.2. Preparation of CBC Daughter Solutions</title><p>From the initially prepared CBC stock solution, daughter solutions were prepared at concentrations of 0.02 mg/mL, 0.04 mg/mL, 0.05 mg/mL, 0.06 mg/mL, 0.08 mg/mL and 0.1 mg/mL.</p></sec><sec id="s2_4_3"><title>2.4.3. Preparation of Sample Solutions</title><p>100 mg of sample syrup was weighed and then transferred to 100 mL volumetric flasks (four). All flasks were made up to the mark with 0.1 N NaOH to give concentrations of 1 mg/mL. 0.5 mL of each of the above solutions was then taken and placed in a further 10 mL volumetric flasks (four) to give a concentration of 0.05 mg/mL.</p></sec><sec id="s2_4_4"><title>2.4.4. Development of the Assay Method</title><p>Validation parameters such as: linearity, precision, accuracy and limits of detection and quantification were evaluated according to the IHT validation procedures [<xref ref-type="bibr" rid="scirp.121825-ref20">20</xref>] to set up the assay.</p><p>• Linearity</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> List of samples used for the study</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Pharmaceutical specialty</th><th align="center" valign="middle" >Dosage</th><th align="center" valign="middle" >Coding</th><th align="center" valign="middle" >Batch numbers</th></tr></thead><tr><td align="center" valign="middle" >RHINATHIOL<sup>&#174;</sup></td><td align="center" valign="middle" >5%</td><td align="center" valign="middle" >RNTL</td><td align="center" valign="middle" >8K1401</td></tr><tr><td align="center" valign="middle" >FLUDIBRONC<sup>&#174;</sup></td><td align="center" valign="middle" >5%</td><td align="center" valign="middle" >FDBC</td><td align="center" valign="middle" >20119/2</td></tr><tr><td align="center" valign="middle" >MEDIBRONC<sup>&#174;</sup></td><td align="center" valign="middle" >5%</td><td align="center" valign="middle" >MDBC</td><td align="center" valign="middle" >V002</td></tr><tr><td align="center" valign="middle" >CARBOTOUX</td><td align="center" valign="middle" >5%</td><td align="center" valign="middle" >CBTX</td><td align="center" valign="middle" >19P0509A</td></tr></tbody></table></table-wrap><p>It was evaluated by determining the coefficient of determination R<sup>2</sup> deduced by the calibration curve. It ranged from 0.02 to 0.1 mg/mL. A spectral scan in the range of 200 to 400 nm was performed to determine λmax. It was 217 nm. The spectrophotometer was then configured at 217 nm for the taking of readings of each daughter solution (n = 3). The average of the absorbances corresponding to each concentration level of the daughter solutions was used to plot the CBC RS calibration curve (<xref ref-type="fig" rid="fig2">Figure 2</xref>).</p><p>• Loyalty</p><p>Six separate 10 mL volumetric flasks containing daughter solutions of the RS standard at C = 0.05 mg/mL were prepared. Repeatability or intra-day precision was determined by taking three readings (n = 3) for each volumetric flask in the spectrophotometer on the same day (<xref ref-type="table" rid="table2">Table 2</xref>). The inter-day precision was determined by also taking three readings (n = 3) per volumetric flask on three consecutive days with the daughter solution of RS standard at C = 0.04 mg/mL. The average absorbance of the three sets of readings/vial and the coefficients of variation (RSD) were calculated for each test (<xref ref-type="table" rid="table3">Table 3</xref>).</p><p>• Accuracy</p><p>It was carried out by the metered addition method. To a quantity corresponding to 50 &#181;g of the sample solution, three different additions of 40 &#181;g, 50 &#181;g and 60 &#181;g of the reference solution RS were made to three separate 10 mL volumetric flasks.) The absorbances obtained after reading were converted to &#181;g /mL using the equation line and then to &#181;g (by multiplying the concentration obtained from the equation line by the total volume of the different mixtures). The recovery rate was then determined (<xref ref-type="table" rid="table4">Table 4</xref>).</p><p>• Limit of detection (LOD) and limit of quantification (LOQ)</p><p>These were assessed by successive dilutions of CBC RS at 0.02 mg/mL to 1/2, 1/10, 1/20 and 1/200 (<xref ref-type="table" rid="table5">Table 5</xref>).</p></sec><sec id="s2_4_5"><title>2.4.5. Determination of CBC Content in Syrup Samples</title><p>The content of CBC in the 5% CBC syrup samples was quantified and the data are listed in (<xref ref-type="table" rid="table6">Table 6</xref>).</p></sec><sec id="s2_4_6"><title>2.4.6. Influence of Physico-Chemical Parameters on CBC Content: Case of RNTL 5%</title><p>• Influence of physical parameters</p><p>The influence of temperature was studied by preparing three paired solutions of RS and RNTL 5% at 0.05 mg/mL and subjecting them to different temperatures (25˚C, 30˚C, 37˚C and 40˚C) for one hour. The absorbance versus temperature curve was plotted (<xref ref-type="fig" rid="fig4">Figure 4</xref>). The previously prepared pairwise solutions were exposed to laboratory light for four successive days. The absorbances were measured each day after exposure to light and noted. The values obtained were used to plot the influence of light on the CBC content of RS and RNTL 5% as a function of time (<xref ref-type="fig" rid="fig5">Figure 5</xref>).</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Intra-day reliability of the method</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Concentration (mg/mL)</th><th align="center" valign="middle" >Average absorbance</th><th align="center" valign="middle" >Mean &#177; Standard deviation</th><th align="center" valign="middle" >RSD (%)</th></tr></thead><tr><td align="center" valign="middle" >0.05</td><td align="center" valign="middle" >0.530</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >0.05</td><td align="center" valign="middle" >0.533</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >0.05</td><td align="center" valign="middle" >0.534</td><td align="center" valign="middle" >0.532 &#177; 0.002</td><td align="center" valign="middle" >0.338</td></tr><tr><td align="center" valign="middle" >0.05</td><td align="center" valign="middle" >0.530</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >0.05</td><td align="center" valign="middle" >0.534</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >0.05</td><td align="center" valign="middle" >0.532</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Inter-day reliability of the method</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Concentration (mg/mL)</th><th align="center" valign="middle" >Day 1</th><th align="center" valign="middle" >Day 2</th><th align="center" valign="middle" >Day 3</th></tr></thead><tr><td align="center" valign="middle" >0.04</td><td align="center" valign="middle" >0.382</td><td align="center" valign="middle" >0.435</td><td align="center" valign="middle" >0.261</td></tr><tr><td align="center" valign="middle" >0.04</td><td align="center" valign="middle" >0.381</td><td align="center" valign="middle" >0.438</td><td align="center" valign="middle" >0.263</td></tr><tr><td align="center" valign="middle" >0.04</td><td align="center" valign="middle" >0.383</td><td align="center" valign="middle" >0.436</td><td align="center" valign="middle" >0.262</td></tr><tr><td align="center" valign="middle" >0.04</td><td align="center" valign="middle" >0.381</td><td align="center" valign="middle" >0.437</td><td align="center" valign="middle" >0.263</td></tr><tr><td align="center" valign="middle" >0.04</td><td align="center" valign="middle" >0.379</td><td align="center" valign="middle" >0.439</td><td align="center" valign="middle" >0.262</td></tr><tr><td align="center" valign="middle" >0.04</td><td align="center" valign="middle" >0.377</td><td align="center" valign="middle" >0.436</td><td align="center" valign="middle" >0.262</td></tr><tr><td align="center" valign="middle" >Average</td><td align="center" valign="middle" >0.381</td><td align="center" valign="middle" >0.437</td><td align="center" valign="middle" >0.262</td></tr><tr><td align="center" valign="middle" >Standard deviation</td><td align="center" valign="middle" >0.002</td><td align="center" valign="middle" >0.002</td><td align="center" valign="middle" >0.001</td></tr><tr><td align="center" valign="middle" >RSD (%)</td><td align="center" valign="middle" >0.050</td><td align="center" valign="middle" >0.387</td><td align="center" valign="middle" >0.200</td></tr></tbody></table></table-wrap><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Accuracy of the method</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Sample quantity (&#181;g)</th><th align="center" valign="middle" >Amount of added RS (&#181;g)</th><th align="center" valign="middle" >Total amount recovered (&#181;g)</th><th align="center" valign="middle"  colspan="2"  >Recovery rate (%)</th></tr></thead><tr><td align="center" valign="middle" >50</td><td align="center" valign="middle" >40</td><td align="center" valign="middle"  colspan="2"  >8.930</td><td align="center" valign="middle" >98.90</td></tr><tr><td align="center" valign="middle" >50</td><td align="center" valign="middle" >40</td><td align="center" valign="middle"  colspan="2"  >8.947</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >50</td><td align="center" valign="middle" >50</td><td align="center" valign="middle"  colspan="2"  >9.915</td><td align="center" valign="middle" >100.000</td></tr><tr><td align="center" valign="middle" >50</td><td align="center" valign="middle" >50</td><td align="center" valign="middle"  colspan="2"  >10.085</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >50</td><td align="center" valign="middle" >60</td><td align="center" valign="middle"  colspan="2"  >10.960</td><td align="center" valign="middle" >100.450</td></tr><tr><td align="center" valign="middle" >50</td><td align="center" valign="middle" >60</td><td align="center" valign="middle"  colspan="2"  >11.090</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><table-wrap id="table5" ><label><xref ref-type="table" rid="table5">Table 5</xref></label><caption><title> Limit of detection and limit of quantification of the method</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Dilution factor</th><th align="center" valign="middle" >Concentration (mg/mL)</th><th align="center" valign="middle" >Absorbances</th></tr></thead><tr><td align="center" valign="middle" >1/2</td><td align="center" valign="middle" >0.0100</td><td align="center" valign="middle" >0.199</td></tr><tr><td align="center" valign="middle" >1/20</td><td align="center" valign="middle" >0.0010</td><td align="center" valign="middle" >0.020</td></tr><tr><td align="center" valign="middle" >1/200</td><td align="center" valign="middle" >0.0001</td><td align="center" valign="middle" >0.000</td></tr></tbody></table></table-wrap><table-wrap id="table6" ><label><xref ref-type="table" rid="table6">Table 6</xref></label><caption><title> Amount of CBC contained in the samples</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Samples</th><th align="center" valign="middle" >Average absorbance</th><th align="center" valign="middle" >Quantity CBC (g/100mL)</th><th align="center" valign="middle" >USP Standard 38 (g/100mL)</th></tr></thead><tr><td align="center" valign="middle" >RNTL 5%</td><td align="center" valign="middle" >0.505</td><td align="center" valign="middle" >4.887</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >FDBC 5%</td><td align="center" valign="middle" >0.483</td><td align="center" valign="middle" >4.740</td><td align="center" valign="middle" >4.500 &#224; 5.500</td></tr><tr><td align="center" valign="middle" >MDBC 5%</td><td align="center" valign="middle" >0.500</td><td align="center" valign="middle" >4.964</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >CBTX 5%</td><td align="center" valign="middle" >0.506</td><td align="center" valign="middle" >5.030</td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>• Influence of chemical parameters</p><p>Eleven paired solutions of RS and RNTL 5% at 0.05 mg/mL were prepared and placed in contact with 0.1 N HCl for one hour in order to obtain solutions with a pH of 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 respectively. The reading of these different solutions made it possible to obtain the evolution curve of the pH and the concentration of CBC contained in the RS and the RNTL 5% (<xref ref-type="fig" rid="fig6">Figure 6</xref>). These same two solutions (one RS and one CBC) were also put in contact with 10 mL of 0.54 mg/mL bile salt solution. A contact time of one hour was also observed before the different readings were taken.</p></sec></sec><sec id="s2_5"><title>2.5. Expression of Data</title><p>The data were obtained using MICROSOFT EXCEL 2016 software and were expressed as mean &#177; standard deviation and RSD (%). They were also compared to the USP 38 pharmacopoeia data [<xref ref-type="bibr" rid="scirp.121825-ref21">21</xref>].</p></sec></sec><sec id="s3"><title>3. Results and Discussion</title><p>• Determination of the detection wavelength λmax</p><p>Prior to the study of the validation parameters, we proceeded to the determination of the maximum absorption wavelength λmax of the CBC by performing a spectral scan from 200 nm to 400 nm. This spectral scan allowed us to detect the maximum absorption wavelength λmax of the CBC which is 217 nm. This λmax is substantially identical to that obtained by Rele R et al. [<xref ref-type="bibr" rid="scirp.121825-ref22">22</xref>] which was 215 nm. On the other hand, this λmax differs from that performed by Pargaonka G et al. [<xref ref-type="bibr" rid="scirp.121825-ref18">18</xref>] who found a λmax of 259 nm. This difference in wavelength could be justified by the fact that in the present study, the CBC was dissolved in an aqueous medium and the absorbance reading was done directly with the spectrophotometer whereas in the study of Pargaonka G et al. [<xref ref-type="bibr" rid="scirp.121825-ref18">18</xref>] a complexation reaction between the CBC and nickel in a non-aqueous medium was required prior to the spectrophotometer reading.</p><p>• Linearity</p><p>This was determined by assessing the coefficient of determination R<sup>2</sup> obtained from the calibration curve. This coefficient was 0.9993. Our result is in accordance with USP 38 [<xref ref-type="bibr" rid="scirp.121825-ref21">21</xref>] which indicates that the coefficient of determination must be greater than 0.9950. Our method is therefore linear (<xref ref-type="fig" rid="fig3">Figure 3</xref>). Our result is superposable to the R<sup>2</sup> obtained by Chauhan K et al. [<xref ref-type="bibr" rid="scirp.121825-ref23">23</xref>] in their study on the validation of a liquid chromatography (HPTLC) method for the determination of CBC in pharmaceutical products.</p><p>• Loyalty</p><p>It was evaluated by intra-day and inter-day fidelity, which each gave respective RSD of 0.338% for the former (<xref ref-type="table" rid="table2">Table 2</xref>) and 0.050% to 0.387% for the latter over three successive days (<xref ref-type="table" rid="table3">Table 3</xref>). Our method complies with the RSD given by USP 38 [<xref ref-type="bibr" rid="scirp.121825-ref21">21</xref>] which stipulates that the RSD for intra-day and inter-day fidelity should be less than 1% and 1.5% respectively. Therefore our method is faithful.</p><p>• Accuracy</p><p>It gave average recovery rates that ranged from 98.490% to 100.450% for CBC RS quantity levels of 40 &#181;g, 50 &#181;g and 60 &#181;g added to the sample solution. These values are in accordance with the specifications given by USP 38 Pharmacopoeia [<xref ref-type="bibr" rid="scirp.121825-ref21">21</xref>] which recommends that the average recovery rate be contained within the acceptability range of 98% to 102%. Our method is therefore accurate like Rele Rajan V [<xref ref-type="bibr" rid="scirp.121825-ref24">24</xref>] who found an average recovery rate of 100.74% in his study (<xref ref-type="table" rid="table4">Table 4</xref>).</p><p>• The limit of detection (LOD) and the limit of quantification (LOQ)</p><p>These are 0.0001 mg/mL for the limit of detection and 0.0010 mg/mL for the limit of quantification. These different limits highlight the sensitivity of our method for the determination of CBC in RNTL 5% syrup (<xref ref-type="table" rid="table5">Table 5</xref>). These limits of detection and quantification are superimposed on those found by Rele Rajan V [<xref ref-type="bibr" rid="scirp.121825-ref24">24</xref>] which were 0.0004 mg/mL and 0.0012 mg/mL respectively.</p><p>• Quantification of CBC in syrup samples</p><p>The content of CBC in our syrup samples was 97.73% or 4.887 g/100mL for RNTL 5%, 94.80% or 4.740 g/100mL for FDBC 5%, 99.28% or 4.964 g/100mL for MDBC 5% and 100.59% or 5.030 g/100mL for CBTX 5%. These results are in accordance with the specifications given by the USP 38 Pharmacopoeia [<xref ref-type="bibr" rid="scirp.121825-ref8">8</xref>] for the assay of samples, which stipulates that the content of active ingredient must be between 90% and 110% of the quantity mentioned on the secondary packaging of the drug.</p><p>• Influence of physico-chemical factors: the case of RNTL 5%.</p><p>When the temperature varies from 25˚C to 40˚C, the CBC concentrations in the RS (reference) and in the tapped syrup of RNTL 5% (sample) evolve respectively from 0.0201 mg/mL to 0.057 mg/mL for the former and 0.047 mg/mL to 0.089 mg/mL for the latter. This evolution could be explained by the fact that by-products of this rise in temperature appear, and these would absorb at λmax = 217 nm. The results obtained differ from those of Taha E.A et al. [<xref ref-type="bibr" rid="scirp.121825-ref25">25</xref>], who obtained a decrease in absorbances as the temperature increased. These results show that temperature has an influence on CBC by changing its content (<xref ref-type="fig" rid="fig4">Figure 4</xref>). Regarding the effect of light, the lack of variation in CBC concentration in RS and RNTL 5% could suggest that light does not influence CBC content after the four days tested (<xref ref-type="fig" rid="fig5">Figure 5</xref>). For pH values ranging from 12 to 7, the concentrations of CBC in RS and RNTL 5% decrease rapidly from 0.031 mg/mL to 0.0007 mg/mL for the former and from 0.044 mg/mL to 0.0055 mg/mL for the latter. They stabilise at pH values below 7 (<xref ref-type="fig" rid="fig6">Figure 6</xref>). This result could be explained by the fact that after pH = 7, all the quantities of CBC contained in these drug matrices have been degraded or neutralised, so there is no more CBC in these solutions. The pH therefore has an influence on the CBC content of these drug matrices (CBC and RNTL 5%). The contact of RS and RNTL 5% with the bile salt solution showed a slight increase in the CBC concentration. From 0.06 to 0.08 mg/mL in RS and from 0.017 to 0.0206 mg/mL in RNTL 5% (<xref ref-type="table" rid="table7">Table 7</xref>). This would indicate the appearance of secondary products that would absorb in this</p><table-wrap id="table7" ><label><xref ref-type="table" rid="table7">Table 7</xref></label><caption><title> Evolution of the amount of CBC under the influence of bile salts</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle"  colspan="2"  >Concentration CBC (mg/mL)</th></tr></thead><tr><td align="center" valign="middle" >Time (min)</td><td align="center" valign="middle" >RS</td><td align="center" valign="middle" >RNTL 5%</td></tr><tr><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0,006</td><td align="center" valign="middle" >0.017</td></tr><tr><td align="center" valign="middle" >60</td><td align="center" valign="middle" >0,008</td><td align="center" valign="middle" >0.0206</td></tr></tbody></table></table-wrap><p>same wavelength range (200 nm to 400 nm). Bile salts therefore have an influence on CBC. It would therefore be wise to administer CBC away from meals to reduce the impact of bile salts, which are produced in abundance in the digestive tract during large, fatty meals. This result is in line with the manufacturers’ recommendations that CBC should be taken away from meals [<xref ref-type="bibr" rid="scirp.121825-ref12">12</xref>].</p></sec><sec id="s4"><title>4. Conclusions</title><p>The method for the determination of CBC in the opened syrup samples developed according to IHT guidelines during the study was satisfactory, i.e. linear, precise and accurate. It was therefore possible to determine the quantities of CBC contained in these opened syrup samples. These analysed quantities were thus in conformity with the specifications of the USP 38 pharmacopoeia version 2015.</p><p>Subsequently, RS and RNTL 5% were exposed to different physico-chemical parameters (temperature, light, bile salts and pH) to study the behaviour of CBC in these different matrices. It was found that the variation of the amount of CBC in the matrices was proportional to the variation of pH and temperature and stable over time in the presence of light. As the influence of light on the CBC content was limited to four days, further tests will have to be carried out in order to determine the fate of the influence of light on the CBC content of these drug matrices in the long term. The evolution of the CBC content in the opened syrup of RNTL 5% is almost identical to that in the RS when the physico-chemical conditions under which these drug matrices are found are varied.</p><p>Nevertheless, in order to highlight the consequences of improper storage of opened medicines and to better understand the behaviour of several active ingredients with respect to these numerous exposure factors, it would be more judicious to extend this study to the other pharmaceutical specialities identified in this study with a wide range of in vitro physicochemical exposure factors.</p></sec><sec id="s5"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest regarding the publication of this paper.</p></sec><sec id="s6"><title>Cite this paper</title><p>Kouame, J.-K., Yehe, M.D., Able, C.N., De Paul Ovi, V., Broh, H.T., Ngantchouko, C.B.N. and Gbassi, G.K. (2022) Influence of Some Physico-Chemical Exposure Factors on the Carbocysteine Content of an Opened Pharmaceutical Product. American Journal of Analytical Chemistry, 13, 495-505. https://doi.org/10.4236/ajac.2022.1312033</p></sec></body><back><ref-list><title>References</title><ref id="scirp.121825-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Niaufre, C. (2014) Le trafic de faux médicaments en Afrique de l’Ouest: Filières d’approvisionnement et réseaux de distribution (Nigeria, Bénin, Togo, Ghana).</mixed-citation></ref><ref id="scirp.121825-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Rbah, Y. (2015) Les médicaments entamés: Etude dans les ménages de la ville de Salé.</mixed-citation></ref><ref id="scirp.121825-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Bouameur, S., Brahim, A., Bounab, M. and Khellifi, A. (2022) Stabilité des médicaments parentéraux dans le circuit hospitalier. Journal de La Faculté de Médecine.</mixed-citation></ref><ref id="scirp.121825-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">(2003) Guideline I. Stability Testing of New Drug Substances and Products. Q1A (R2), Current Step; 4.</mixed-citation></ref><ref id="scirp.121825-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Newton, P.N., Green, M.D., Fernández, F.M., Day, N.P. and White, N.J. (2006) Counterfeit Anti-Infective Drugs. The Lancet Infectious Diseases, 6, 602-613. https://doi.org/10.1016/S1473-3099(06)70581-3</mixed-citation></ref><ref id="scirp.121825-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Kelesidis, T., Kelesidis, I., Rafailidis, P.I. and Falagas, M.E. (2007) Counterfeit or Substandard Antimicrobial Drugs: A Review of the Scientific Evidence. Journal of Antimicrobial Chemotherapy, 60, 214-236. https://doi.org/10.1093/jac/dkm109</mixed-citation></ref><ref id="scirp.121825-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Vidjro, S.W. (2015) Etude de Stabilite D’UN Sirop de Paracetamol Pediatrique: Effet des Conditions de Conservation D’usage Courant.</mixed-citation></ref><ref id="scirp.121825-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Jassim, A.-M. (2010) In-Home Drug Storage and Self-Medication with Antimicrobial Drugs in Basrah, Iraq. Oman Medical Journal, 25, 79-87. https://doi.org/10.5001/omj.2010.25</mixed-citation></ref><ref id="scirp.121825-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Shankar, P., Kumar, P., Theodore, A., Partha, P. and Shenoy, N. (2003) A Survey of Drug Use Patterns in Western Nepal. Singapore Medical Journal, 44, 352-356.</mixed-citation></ref><ref id="scirp.121825-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Fainzang, S. (2003) Les médicaments dans l’espace privé: Gestion individuelle ou collective. Anthropologie et Sociétés, 27, 139-154. https://doi.org/10.7202/007450ar</mixed-citation></ref><ref id="scirp.121825-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">(2009) The British Pharmacopoeia. Volume 1.</mixed-citation></ref><ref id="scirp.121825-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">(n.d.) Vidal 2022, l’intélligence médicale au service du soin.</mixed-citation></ref><ref id="scirp.121825-ref13"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Davis</surname><given-names> S. </given-names></name>,<etal>et al</etal>. (<year>2022</year>)<article-title>Carbocisteine</article-title><source> SA Pharmaceutical Journal</source><volume> 89</volume>,<fpage> 20</fpage>-<lpage>22</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.121825-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Goebel, K. and Rolim, C.M.B. (2007) Validation of UV Spectrophotometric and HPLC Methods for Quantitative Determination of Atenolol in Pharmaceutical Preparations. Latin American Journal of Pharmacy, 26, 765-770.</mixed-citation></ref><ref id="scirp.121825-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Walash, M.I., El-Brashy, A.M., Metwally, M.E.-S. and Abdelal, A.A. (2004) Fluorimetric Determination of Carbocisteine and Ethionamide in Drug Formulation. Acta Chimica Slovenica, 51, 283-291.</mixed-citation></ref><ref id="scirp.121825-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Liang, Y.-Z., Xie, P. and Chan, K. (2004) Quality Control of Herbal Medicines. Journal of Chromatography B, 812, 53-70. https://doi.org/10.1016/S1570-0232(04)00676-2</mixed-citation></ref><ref id="scirp.121825-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Xie, P. (2005) Chromatography Fingerprint of Traditional Chinese Medicine. People’s Medical Publishing House, Beijing, 18-104.</mixed-citation></ref><ref id="scirp.121825-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Pargaonkar, G. and Kaskhedikar, S. (1994) Spectrophotometric Estimation of Amoxycillin and Carbocysteine in Single Dosage Forms by Complexation with Nickel (II). Indian Drugs Bombay, 31, 590-590.</mixed-citation></ref><ref id="scirp.121825-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Grant, K. and Quinn, M. (2018) Avantages du spectrophotomètre UV-Vis Cary 3500 multicuve pour l’analyse des protéines Améliorations de la productivité et de la reproductibilité pour les mesures qualitatives et quantitatives à très faibles volumes.</mixed-citation></ref><ref id="scirp.121825-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">(2022) Guideline IHT. Validation of Analytical Procedures Q2 (R1).</mixed-citation></ref><ref id="scirp.121825-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">(n.d.) USP 38-NF 33. The United States Pharmacopeia and National Formulary Version 2015 Main edition plus Supplements 1 and 2.</mixed-citation></ref><ref id="scirp.121825-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Rele, R. and Rane, D. (2017) Validation of Carbocisteine by Reversed Phase High Performance Liquid Chromatography Method from Active Pharmaceutical Dosage Form. International Journal of ChemTech Research, 10, 583-589.</mixed-citation></ref><ref id="scirp.121825-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Chauhan, K., Mujawar, A. and Quazi, I. (2016) HPTLC Method Development and Validation for Densitometric Analysis of Carbocisteine in Drug Formulation. International Journal of Applied Pharmaceutics, 8, 22-25.</mixed-citation></ref><ref id="scirp.121825-ref24"><label>24</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rele</surname><given-names> R.V. </given-names></name>,<etal>et al</etal>. (<year>2014</year>)<article-title>Spectrophotometric Estimation of Carbocisteine in Bulk and Pharmaceutical Dosage Form by Second Order Derivative Method</article-title><source> Journal of Chemical and Pharmaceutical Research</source><volume> 6</volume>,<fpage> 118</fpage>-<lpage>122</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.121825-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Taha, E.A., Hassan, N.Y., Abdel, A.F. and Abdel, F.L. (2008) Kinetic Spectrophotometic Determination of Acetylcysteine and Carbocisteine in Bulk Powder and in Drug Formulations. ScienceAsia, 34, 107-113. https://doi.org/10.2306/scienceasia1513-1874.2008.34.107</mixed-citation></ref></ref-list></back></article>